| P50 | author | Michael Hallek | Q20752664 |
| | Slawomira Kyrcz-Krzemien | Q114428269 |
| P2093 | author name string | Andreas Engert | |
| | Thomas Elter | |
| | Jingyang Wu | |
| | Branimir Jaksic | |
| | Cynthia Sirard | |
| | Liana Gercheva-Kyuchukova | |
| | Grigoriy Rekhtman | |
| | Mykola Vatutin | |
| | Halyna Pylylpenko | |
| | Tadesuz Robak | |
| P2860 | cites work | Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 |
| | A Multiple Testing Procedure for Clinical Trials | Q28248823 |
| | Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial | Q29396936 |
| | Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 |
| | Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia | Q33374227 |
| | How I treat CLL up front | Q34137158 |
| | Update in the management of chronic lymphocytic leukemia | Q37295449 |
| | Chronic lymphocytic leukemia: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up | Q37488948 |
| | State-of-the-art treatment of chronic lymphocytic leukemia | Q37653254 |
| | 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen | Q37659067 |
| | Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. | Q40779596 |
| | Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs | Q41105815 |
| | Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. | Q43145571 |
| | Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia | Q43904550 |
| | Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial | Q46689599 |
| | Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 |
| | A sharper Bonferroni procedure for multiple tests of significance | Q56622251 |
| | Therapy-related leukemia and myelodysplasia: susceptibility and incidence. | Q64991297 |
| P433 | issue | 13 | |
| P921 | main subject | leukemia | Q29496 |
| | lymphocyte | Q715347 |
| | phase III clinical trial | Q42824827 |
| P304 | page(s) | 1204-1213 | |
| P577 | publication date | 2011-10-10 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial | |
| P478 | volume | 12 | |